- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Coverage Trends of Specialty Drugs Create Confusing Situations for Patients
As a result of vertical integration, health plans may have 2 different coverage policies on the medical benefit side and the pharmacy benefit side for the same drug.
The vertical integration of pharmacy benefit managers and insurers has led to strategies that have created confusing and counterintuitive situations for patients to navigate, explained James D. Chambers, PhD, professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.
This transcript has been lightly edited for clarity.
Transcript
There is a trend of specialty drugs being shifted from the medical benefit to the pharmacy benefit. Why are payers doing this and what are some potentially negative consequences of this strategy?
We had a paper published last year that looked within our database of specialty drug coverage decisions, and on occasion, the same health plan had both a medical policy and a pharmacy policy for the same drug. Confusing. Even more confusing was, 15% of the time, the coverage requirements differed—so the step therapy requirements are inconsistent between the medical benefit and the pharmacy benefit. What we were trying to show with this paper is simply that this is very confusing and oftentimes counterintuitive.
Why are we seeing the merging of the medical and the pharmacy in different instances? Historically, of course, physician-administered drugs are in the medical benefit, self-administered drugs in the pharmacy benefit. White bagging and brown bagging are an attempt, I think, for an insurance company to drive patients to their own pharmacy—this vertical integration idea—in order to profit from the drug, from a pharmacy perspective, and to ensure that they're maximizing the return that they're getting from the delivery and administration off the drug. It really is a vertical integration problem.
As outlined in the paper, it's challenging for patients. It might increase waste in the system as well, and it's putting more onus on the patients to collect drugs and to organize things. The system's complicated enough as it stands. Also, it leads to inconsistencies in access, because we see that there's differences in coverage between the medical and pharmacy benefits for the same drugs. It really is a symptom, I think, of the vertical integration of the pharmacy chain in general.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More
